HBM HEALTHCARE INVESTMENTS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 208.5 CHF | +2.96% |
|
+0.24% | +14.18% |
| May. 28 | HBM Healthcare Flags NAV Boost from Yellow Jersey-Johnson & Johnson Deal | MT |
| May. 23 | HBM Healthcare Investments' Portfolio Company to Buy Laboratorios Biopas Group | MT |
Summary
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For several months, analysts have been revising their EPS estimates roughly upwards.
Weaknesses
- With a 2025 P/E ratio at 28.8 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Investment Management & Fund Operators
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +14.18% | 1.61B | D+ | ||
| +18.72% | 3.16B | B- | ||
| +12.50% | 1.76B | - | - | |
| -11.54% | 1.21B | - | - | |
| +22.48% | 813M | B+ | ||
| +6.81% | 647M | - | ||
| +40.10% | 597M | - | D+ | |
| +44.88% | 527M | - | - | |
| -4.17% | 506M | - | - | |
| +103.82% | 375M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- HBMN Stock
- Ratings HBM Healthcare Investments AG
